Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 19/20 | 0.68 |
| ▸ | PIK3CA | P42336 | 18/20 | 0.68 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.47 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.47 |
| ▸ | MTOR | P42345 | 7/20 | 0.47 |
| ▸ | PIK3C3 | Q8NEB9 | 6/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22553125 | 0.83 | PIK3CG (0.49) | PIK3CGPIK3CAPIK3CDPIK3CBMTOR | |
| SCHEMBL17204013 | 0.81 | PIK3CG (0.59) | PIK3CGPIK3CAPIK3CDPIK3CBMTOR | |
| SCHEMBL18502149 | 0.81 | PIK3CG (1.00) | PIK3CGPIK3CAPIK3CDPIK3CBMTOR | |
| SCHEMBL22553129 | 0.81 | PIK3CG (0.67) | PIK3CGPIK3CAPIK3CDPIK3CBMTOR | |
| SCHEMBL18507177 | 0.80 | PIK3CG (0.69) | PIK3CGPIK3CAPIK3CDPIK3CBMTOR | |
| SCHEMBL18507178 | 0.80 | PIK3CG (0.69) | PIK3CGPIK3CAPIK3CDPIK3CBMTOR | |
| SCHEMBL17203630 | 0.80 | PIK3CG (0.84) | PIK3CGPIK3CAPIK3CDPIK3CBMTOR | |
| SCHEMBL18507255 | 0.80 | PIK3CG (0.69) | PIK3CGPIK3CAPIK3CDPIK3CBMTOR | |
| SCHEMBL17203676 | 0.80 | PIK3CG (0.78) | PIK3CGPIK3CAPIK3CDPIK3CBMTOR | |
| SCHEMBL22553100 | 0.79 | PIK3CG (0.67) | PIK3CGPIK3CAPIK3CDPIK3CBMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11306079-B2 | 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors | INCYTE CORPORATION (US) | 2022-04-19 | — | — | US | disclosed |
| US-20200331903-A1 | 3-(5-AMINO-PYRAZIN-2-YL)-BENZENESULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PI3K-GAMMA KINASE INHIBITORS FOR TREATING E.G. CANCER | INCYTE CORPORATION | 2020-10-22 | — | — | US | disclosed |
| CN-106458979-B | Aminopyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | 诺华股份有限公司 | 2020-03-27 | — | — | CN | disclosed |
| US-20180243297-A1 | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG (CH) | 2018-08-30 | — | — | US | disclosed |
| US-10004732-B2 | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG (CH) | 2018-06-26 | — | — | US | disclosed |
| US-10004732-B2 | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG (CH) | 2018-06-26 | — | — | US | disclosed |
| US-10004732-B2 | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | NOVARTIS AG (CH) | 2018-06-26 | — | — | US | disclosed |
| EP-3134397-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | Novartis AG (CH) | 2017-03-01 | — | — | EP | disclosed |
| US-20170042889-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| US-20170042889-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| US-20170042889-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2017-02-16 | — | — | US | disclosed |
| WO-2015162459-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2015-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180243297-A1 | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | PI4KA, PIP5K1B, PIP4K2B | PIK3CG 18/4885PIK3CA 27/4885PIK3CD 15/4885 |
| US-20200331903-A1 | 3-(5-AMINO-PYRAZIN-2-YL)-BENZENESULFONAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PI3K-GAMMA KINASE INHIBITORS FOR TREATING E.G. CANCER | PIK3CG, PIK3R5, PIK3CD | PIK3CG 1/4885PIK3CA 4/4885PIK3CD 3/4885 |
| US-11306079-B2 | 3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors | PIK3CG, PIK3CD, PIK3CA | PIK3CG 1/4885PIK3CA 3/4885PIK3CD 2/4885 |
| US-10004732-B2 | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors | PI4KA, PIP5K1B, PIP4K2B | PIK3CG 18/4885PIK3CA 27/4885PIK3CD 15/4885 |
| US-20170042889-A1 | AMINO PYRAZINE DERIVATIVES AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PI4KA, PIP5K1B, PIP4K2B | PIK3CG 18/4885PIK3CA 27/4885PIK3CD 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.